Eli Lilly and Company (NYSE:LLY) Receives $938.61 Average PT from Brokerages

Shares of Eli Lilly and Company (NYSE:LLY) have earned a consensus recommendation of “Moderate Buy” from the twenty-four research firms that are currently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold recommendation, fifteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $940.00.

LLY has been the subject of a number of recent research reports. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. JPMorgan Chase & Co. decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Morgan Stanley cut their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th.

Insider Activity

In other news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently made changes to their positions in the stock. Werba Rubin Papier Wealth Management lifted its stake in shares of Eli Lilly and Company by 13.1% in the third quarter. Werba Rubin Papier Wealth Management now owns 682 shares of the company’s stock valued at $520,000 after buying an additional 79 shares during the period. Howard Capital Management Inc. lifted its stake in shares of Eli Lilly and Company by 2.8% in the third quarter. Howard Capital Management Inc. now owns 9,044 shares of the company’s stock valued at $6,901,000 after buying an additional 244 shares during the period. Berman McAleer LLC bought a new stake in shares of Eli Lilly and Company in the third quarter valued at about $405,000. National Pension Service lifted its stake in shares of Eli Lilly and Company by 3.2% in the third quarter. National Pension Service now owns 1,592,232 shares of the company’s stock valued at $1,214,873,000 after buying an additional 48,994 shares during the period. Finally, Searle & CO. lifted its stake in shares of Eli Lilly and Company by 4.3% in the third quarter. Searle & CO. now owns 3,500 shares of the company’s stock valued at $2,671,000 after buying an additional 145 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 3.9%

Eli Lilly and Company stock opened at $896.15 on Tuesday. The company’s fifty day simple moving average is $784.74 and its 200-day simple moving average is $772.35. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The stock has a market cap of $848.17 billion, a P/E ratio of 58.57, a P/E/G ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.